Currently browsing: Community News

CAC2 Childhood Cancer Community News Digest (December 12-18)

Assorted News from the Last Week: FDA approves Brentuximab for high-risk Hodgkin Lymphoma in children and adolescents. The Comprehensive Cancer Survivorship Act was introduced to address care planning, transition, navigation, reimbursement, quality, and so much more. It aims to address gaps in survivorship care and develop desperately needed standards to improve the overall patient-centered quality of care and navigation needs of the nation’s 18 million cancer survivors of all ages. Some brides may take photos near a scenic lake, outside a stately chateau or maybe inside an adorable rustic barn.  But CAC2 Member and childhood cancer survivor Riley Stock Wagner, [...] Read more

CAC2 Member Blog–Celebrating the Introduction of The Comprehensive Cancer Survivorship Act

By CAC2 Member Jess Kean, Children's Cancer Cause. The Comprehensive Cancer Survivorship Act was introduced in Congress on December 14, 2022. As the only childhood cancer organization involved in the drafting of this legislation, CAC2 Member Children's Cancer Cause is pleased to share the details of this bill with other CAC2 members in the hopes that the community will join us as we work toward its passage. The Comprehensive Cancer Survivorship Act addresses care planning, transition, navigation, reimbursement, quality, and so much more. It aims to address gaps in survivorship care and develop desperately needed standards to improve the overall [...] Read more

CAC2 Childhood Cancer Community News Digest (December 5-11)

Assorted News from the Last Week: For many patients, one of the most antagonizing parts of a hospital visit is paying for parking. Those parking fees aren’t just an annoyance for the sick and injured, according to a new paper in the Journal of Medical Imaging and Radiation Sciences. The charges are actually eating into their financial well-being, particularly for people who have cancer and have to make frequent visits to the hospital for treatments like radiation and chemotherapy. Children diagnosed with diffuse midline gliomas often die within a year after their initial diagnosis since there are no effective treatments yet [...] Read more

Save the Date! Action Days 2023 Returns to Washington, D.C.

By Guest Blogger Sarah Milberg, Co-Chair of the Alliance for Childhood Cancer and Director of Government Relations and Advocacy for the St. Baldrick’s Foundation Thanks to advocates like you, we have been able to make great progress on important childhood cancer issues before Congress. The Alliance for Childhood Cancer is excited to announce that Action Days 2023 will return back to Washington, D.C. from April 24-25, 2023. Registration will open in early 2023. Action Days gives you an opportunity to speak with your members of Congress and their staff to advocate for important childhood cancer issues before Congress. Sharing your story next […]

Read more

CAC2 Childhood Cancer Community News Digest (November 28-December 4)

Assorted News from the Last Week: "I’d like to introduce you to Josh. . .  Josh, a sound engineer, is also a childhood cancer survivor who lives with profound hearing loss. Josh has a deep love of music. It has been a constant struggle for most of his life. The side effects of chemotherapy treatment robbed him of quality of life." High radiosensitivity of the meninges was observed in pediatric patients with cancer treated before 10 years of age, supporting the use of reduced dose whole brain irradiation and the prioritization of approaches that limit radiation exposure in healthy tissue, [...] Read more

CAC2 Childhood Cancer Community News Digest (November 21-27)

Assorted News from the Last Week: CAC2 Member Mary Beth Collins explains the importance of the new FDA approval of Pedmark:  "With the FDA’s recent approval of Pedmark (an injectable formulation of sodium thiosulfate ("STS"), children are protected from cisplatin’s ototoxicity.  This development is substantial for children in treatment because it maintains their hearing, providing a better quality of life." Hayley Arceneaux became the youngest American to go to space last year after she spent three days in orbit on Space-X's Inspiration rocket. She is telling her story in a new book. Pediatric patients who receive central nervous system (CNS)-directed treatment for [...] Read more

CAC2 Childhood Cancer Community News Digest (November 14-20)

Assorted News from the Last Week: CAC2 Member Joe Baber reflects on the Gabriella Miller Kids First 2.0 legislation pending in Congress:  "We’re all thankful when there are lifesaving therapies and at the very same time, we are fearful of relapse, side effects of the drugs, chemotherapy, radiation, surgery and even death.  These contrary and parallel emotions seem to be linked in partnership throughout the childhood cancer experience." This month, Dr. Gregory Reaman was named by the Childhood Cancer Data Initiative (CCDI) as the new Scientific Director. In this role, Dr. Reaman will develop, direct, and coordinate CCDI programs and [...] Read more

Community News–Childhood Cancer Data Initiative Welcomes Dr. Gregory Reaman as Its New Scientific Director

This month, Dr. Gregory Reaman was named by the Childhood Cancer Data Initiative (CCDI) as the new Scientific Director. In this role, Dr. Reaman will develop, direct, and coordinate CCDI programs and initiatives, as well as provide scientific oversight and recommendations to drive CCDI’s vision and progress. He comes to NCI most recently from the US Food and Drug Administration, with a career dedicated to caring for children with cancer and decades of leadership experience improving childhood cancer research. The CCDI team isn’t the only part of CCDI that expanded. NCI released initial data from the CCDI Molecular Characterization Initiative, [...] Read more

CAC2 Childhood Cancer Community News Digest (November 7-13)

Assorted News from the Last Week: The FDA has approved brentuximab vedotin (Adcetris) in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide (AVE-PC) in pediatric patients aged 2 years and older with previously untreated, high-risk classical Hodgkin lymphoma.  Read more:  Administration of a targeted therapy for children with high-risk Hodgkin lymphoma (HL) was found to significantly decrease relapse rates in a large multicenter clinical trial conducted by the Children’s Oncology Group (COG) and published in The New England Journal of Medicine. Researchers have used CRISPR/Cas9 technology to engineer donor T cells to try to treat seriously ill children with resistant [...] Read more

Guest Blog–The Fit for Filing Group at ACCELERATE

Blogged with permission and thanks by the ACCELERATE Fit for Filing Working Group   The ACCELERATE PLATFORM’S Fit for Filing (FFF) group was formed in 2019 to explore the issues of academic-led trials that typically do not produce data that is fit-for-filing to gain marketing approval by regulatory agencies.   The scope of Fit for Filing (FFF) is to develop best principles on how to design and deliver an academic or academic & industry collaborative trial with a dataset that can be included in a package for regulatory filing.Objectives of the FFF working group are: Define the barriers and propose solutions to ensure […]

Read more

Enquire now

Give us a call or fill in the form below and we will contact you. We endeavor to answer all inquiries within 24 hours on business days.